Bespoke Extracts (BSPK) Income from Continuing Operations (2011 - 2025)
Bespoke Extracts (BSPK) reported Income from Continuing Operations of 78088.0 for Q3 2025, up 71.67% on a YoY basis from 45487.93 in Q3 2024, and up 61.93% sequentially from 205106.0 in Q2 2025.
Bespoke Extracts (BSPK) Income from Continuing Operations (2011 - 2025) Analysis & Trends
Bespoke Extracts (BSPK) has 15 years of Income from Continuing Operations data on file, last reported at 78088.0 in Q3 2025.
- For the quarter ending Q3 2025, Income from Continuing Operations rose 71.67% year-over-year to 78088.0; the trailing twelve-month figure through Sep 2025 stood at 730564.0 (up 34.75% YoY), and the FY2024 full-year result was 1037475.0, up 30.03% from the prior year.
- Income from Continuing Operations rose to 78088.0 in Q3 2025, from 205106.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 3588302.0 in Q3 2021 to a low of 1134125.0 in Q3 2022.
- A 5-year average of 208527.58 and a median of 299571.0 in 2021 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations surged 212.31% in 2021 and rose 8.59% in 2024, its largest moves.
- Tracing BSPK's Income from Continuing Operations over 5 years: stood at 226984.0 in 2021, then tumbled by 539.51% to 997626.0 in 2022, then jumped by 73.03% to 269087.0 in 2023, then jumped by 30.56% to 186849.0 in 2024, then jumped by 58.21% to 78088.0 in 2025.
- Business Quant data shows BSPK's Income from Continuing Operations at 78088.0 in Q3 2025, 205106.0 in Q2 2025, and 260521.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -3.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 274.90 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Bespoke Extracts | 1.12 Mn | 1.11 Mn | 234,175.00 | -78,088.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -78,088.00 |
| Jun 30, 2025 | -205,106.00 |
| Mar 31, 2025 | -260,521.00 |
| Dec 31, 2024 | -186,849.00 |
| Sep 30, 2024 | -275,613.00 |
| Jun 30, 2024 | -260,895.00 |
| Mar 31, 2024 | -314,118.00 |
| Dec 31, 2023 | -269,087.00 |
| Sep 30, 2023 | -301,529.00 |
| Jun 30, 2023 | -464,915.00 |
| Mar 31, 2023 | -440,620.00 |
| Dec 31, 2022 | -997,626.00 |
| Sep 30, 2022 | -1.13 Mn |
| Jun 30, 2022 | -1.01 Mn |
| Mar 31, 2022 | -972,494.00 |
| Nov 30, 2021 | 226,984.00 |
| Aug 31, 2021 | 3.59 Mn |
| May 31, 2021 | -299,571.00 |
| Feb 28, 2021 | -304,171.00 |
| Nov 30, 2020 | -202,106.00 |